For research and educational purposes only. This page is a factual research reference, not medical advice. Any dosing figures shown are amounts reported in the research literature, provided for educational context — not instructions or recommendations for human use.
Overview
A 52-week randomized trial enrolled 656 insulin-treated people with type 2 diabetes and compared adjunctive pramlintide with placebo. The study assessed glucose control, body weight and adverse events.
At a glance
ClassAmylin analog
CategoryGLP-1 Family
Page purposeResearch and educational reference
Regulatory statusThis page summarizes the cited research. Regulatory authorization is specific to a product, indication and jurisdiction; consult the relevant regulator for current labeling.
Selected evidence, in context
A closer reading of selected linked publications. This is not a systematic review, an evidence grade or a complete account of safety and effectiveness.
656 insulin-treated adults with type 2 diabetes; 52 weeks
Research question
Did adding pramlintide to insulin improve long-term glycemic and weight outcomes?
Reported finding
One active-treatment group achieved a larger HbA1c reduction than placebo and lost an average 1.4 kg, versus a 0.7 kg gain with placebo. Nausea was the most common adverse event.
What this cannot establish
This was adjunctive treatment in insulin-treated type 2 diabetes. It does not establish standalone weight-management effects or outcomes in people without diabetes.
Pramlintide is an analog of amylin, a pancreatic hormone involved in post-meal glucose regulation. It is not a GLP-1 receptor agonist; it is grouped here for metabolic comparisons.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Pramlintide appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Amylin signalingType 2 diabetes
Key characteristics
Results concern adjunctive use in an insulin-treated study population. They cannot be transferred to a different compound, a supplier blend or use without clinical supervision.
How it compares
Results concern adjunctive use in an insulin-treated study population. They cannot be transferred to a different compound, a supplier blend or use without clinical supervision.
Commonly studied alongside
Compounds frequently researched together with Pramlintide in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Side-by-side pages for the pairings the literature already documents for Pramlintide, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.
Results concern adjunctive use in an insulin-treated study population. They cannot be transferred to a different compound, a supplier blend or use without clinical supervision.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
Publications indexed in PubMed and linked to this profile, including original studies and reviews. Publication labels reflect PubMed indexing, not evidence strength. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial Diabetes Care, 2003. PubMed 12610038
Bibliographic metadata refreshed from PubMed on 2026-09-20. This checks the record identity and metadata; it is not a new review of every scientific claim. A reference may concern a related molecule or formulation: read its methods and the context above. See the editorial policy.
